Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Gastrointestinal 3Dermatologic 3Genitourinary 2Endocrine 2Breast 2Plasma cell 1Myeloid 1Gynecologic 1

Conditions

Somatostatinoma 2Carcinoma, Islet Cell 2Vipoma 1Pituitary Neoplasms 1Insulinoma 1Growth Hormone-Secreting Pituitary Adenoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Biological Therapy × Endocrine × Clear all
NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡